Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 2.58
ALQA's Cash to Debt is ranked higher than
56% of the 729 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.63 vs. ALQA: 2.58 )
Ranked among companies with meaningful Cash to Debt only.
ALQA' s Cash to Debt Range Over the Past 10 Years
Min: 0.05  Med: 10000.00 Max: No Debt
Current: 2.58
Equity to Asset 0.57
ALQA's Equity to Asset is ranked lower than
58% of the 677 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. ALQA: 0.57 )
Ranked among companies with meaningful Equity to Asset only.
ALQA' s Equity to Asset Range Over the Past 10 Years
Min: 0.57  Med: 0.87 Max: 0.99
Current: 0.57
0.57
0.99
F-Score: 4
Z-Score: -1.20
M-Score: -1.17
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -242.66
ALQA's Operating margin (%) is ranked lower than
92% of the 686 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.82 vs. ALQA: -242.66 )
Ranked among companies with meaningful Operating margin (%) only.
ALQA' s Operating margin (%) Range Over the Past 10 Years
Min: -1119.69  Med: -464.77 Max: -51.07
Current: -242.66
-1119.69
-51.07
Net-margin (%) -227.51
ALQA's Net-margin (%) is ranked lower than
93% of the 687 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.45 vs. ALQA: -227.51 )
Ranked among companies with meaningful Net-margin (%) only.
ALQA' s Net-margin (%) Range Over the Past 10 Years
Min: -1222.3  Med: -465.38 Max: -52.73
Current: -227.51
-1222.3
-52.73
ROE (%) -75.50
ALQA's ROE (%) is ranked lower than
92% of the 715 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. ALQA: -75.50 )
Ranked among companies with meaningful ROE (%) only.
ALQA' s ROE (%) Range Over the Past 10 Years
Min: -312.57  Med: -72.05 Max: -16.22
Current: -75.5
-312.57
-16.22
ROA (%) -48.12
ALQA's ROA (%) is ranked lower than
91% of the 740 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.67 vs. ALQA: -48.12 )
Ranked among companies with meaningful ROA (%) only.
ALQA' s ROA (%) Range Over the Past 10 Years
Min: -2368.45  Med: -124.42 Max: -15.45
Current: -48.12
-2368.45
-15.45
ROC (Joel Greenblatt) (%) -1754.14
ALQA's ROC (Joel Greenblatt) (%) is ranked lower than
93% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.76 vs. ALQA: -1754.14 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ALQA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -80514.29  Med: -1400.05 Max: -55.94
Current: -1754.14
-80514.29
-55.94
Revenue Growth (3Y)(%) -5.40
ALQA's Revenue Growth (3Y)(%) is ranked lower than
80% of the 585 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. ALQA: -5.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ALQA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: -5.4
Current: -5.4
EBITDA Growth (3Y)(%) -15.90
ALQA's EBITDA Growth (3Y)(%) is ranked lower than
78% of the 531 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. ALQA: -15.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ALQA' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -67.3  Med: 27.40 Max: 106.5
Current: -15.9
-67.3
106.5
EPS Growth (3Y)(%) -15.90
ALQA's EPS Growth (3Y)(%) is ranked lower than
74% of the 487 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.00 vs. ALQA: -15.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ALQA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -46.6  Med: 32.20 Max: 116.7
Current: -15.9
-46.6
116.7
» ALQA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

ALQA Guru Trades in

ALQA Guru Trades in

ALQA Guru Trades in

Q3 2015

ALQA Guru Trades in Q3 2015

Jim Simons 15,900 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with ALQA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.77
ALQA's P/B is ranked higher than
90% of the 936 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.38 vs. ALQA: 0.77 )
Ranked among companies with meaningful P/B only.
ALQA' s P/B Range Over the Past 10 Years
Min: 0.53  Med: 1.81 Max: 23.25
Current: 0.77
0.53
23.25
P/S 2.51
ALQA's P/S is ranked higher than
54% of the 937 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.68 vs. ALQA: 2.51 )
Ranked among companies with meaningful P/S only.
ALQA' s P/S Range Over the Past 10 Years
Min: 2.49  Med: 11.24 Max: 39.24
Current: 2.51
2.49
39.24
Current Ratio 2.83
ALQA's Current Ratio is ranked higher than
61% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.27 vs. ALQA: 2.83 )
Ranked among companies with meaningful Current Ratio only.
ALQA' s Current Ratio Range Over the Past 10 Years
Min: 0.04  Med: 1.79 Max: 96.93
Current: 2.83
0.04
96.93
Quick Ratio 2.56
ALQA's Quick Ratio is ranked higher than
67% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.65 vs. ALQA: 2.56 )
Ranked among companies with meaningful Quick Ratio only.
ALQA' s Quick Ratio Range Over the Past 10 Years
Min: 0.04  Med: 1.42 Max: 96.93
Current: 2.56
0.04
96.93
Days Inventory 148.79
ALQA's Days Inventory is ranked lower than
65% of the 643 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 118.46 vs. ALQA: 148.79 )
Ranked among companies with meaningful Days Inventory only.
ALQA' s Days Inventory Range Over the Past 10 Years
Min: 11.87  Med: 44.34 Max: 106.73
Current: 148.79
11.87
106.73
Days Sales Outstanding 73.10
ALQA's Days Sales Outstanding is ranked higher than
52% of the 585 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.01 vs. ALQA: 73.10 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALQA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 13.55  Med: 33.21 Max: 73.9
Current: 73.1
13.55
73.9
Days Payable 202.32
ALQA's Days Payable is ranked higher than
91% of the 558 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.59 vs. ALQA: 202.32 )
Ranked among companies with meaningful Days Payable only.
ALQA' s Days Payable Range Over the Past 10 Years
Min: 24.61  Med: 84.03 Max: 196.17
Current: 202.32
24.61
196.17

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.23
ALQA's Price/Median PS Value is ranked higher than
97% of the 924 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.14 vs. ALQA: 0.23 )
Ranked among companies with meaningful Price/Median PS Value only.
ALQA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.49  Med: 0.99 Max: 3.12
Current: 0.23
0.49
3.12
Price/Graham Number 1.30
ALQA's Price/Graham Number is ranked higher than
74% of the 703 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.18 vs. ALQA: 1.30 )
Ranked among companies with meaningful Price/Graham Number only.
ALQA' s Price/Graham Number Range Over the Past 10 Years
Min: 2.83  Med: 14.77 Max: 67.95
Current: 1.3
2.83
67.95
Earnings Yield (Greenblatt) (%) -125.95
ALQA's Earnings Yield (Greenblatt) (%) is ranked lower than
97% of the 723 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. ALQA: -125.95 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ALQA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -158.43  Med: 0.00 Max: 0
Current: -125.95
-158.43
0

More Statistics

Revenue(Mil) $12
EPS $ -1.40
Beta2.21
Short Percentage of Float3.35%
52-Week Range $1.42 - 6.55
Shares Outstanding(Mil)27.67

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 16 30 46 61
EPS($) -1.32 -0.91 -0.62 -0.39
EPS without NRI($) -1.32 -0.91 -0.62 -0.39

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:WST, BAX, COV, TMO, COO » details
Alliqua BioMedical Inc a Florida corporation formed on October 21, 1997. It is a biomedical company through its subsidiary providing advanced wound care solutions. The Company's core business includes; advanced wound care and contract manufacturing. The Company develops, manufactures and markets high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. Its subsidiary manufactures and markets its hydrogel products. Its products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies. Together, these technologies enable it to produce gels that can satisfy rigid tolerance specifications with respect to a range of physical characteristics (e.g., thickness, water content, adherence, absorption, moisture vapor transmission rate (a measure of the passage of water vapor through a substance) and release rate) while maintaining product integrity. In July 2012, it began to market two proprietary products, SilverSeal, a hydrogel wound dressing with silver coated fibers, and Hydress, an over-the-counter hydrogel wound dressing. It supplies these gels mainly to the wound care segment of the healthcare industry. The Company's SilverSeal and Hydress dressings are each currently available in two sizes and are used to provide and maintain a moist wound environment. SilverSeal dressings also provide an antimicrobial barrier. On November 14, 2013 Company entered into a license, marketing and development agreement with Anthrogenesis Corporation, Celgene Cellular Therapeutics ("CCT"), an affiliate of Celgene Corporation, pursuant to which CCT granted an exclusive, royalty-bearing license in its intellectual property related to certain placental based products, including the wound care products Extracellular Matrix ("ECM"), a suite of advanced wound management products made from extracellular matrix derived from the human placenta and Biovance, a collagen-based decellularized and dehydrated topical wound covering produced from human amniotic membrane for the management of non-infected partial- and full-thickness wounds; and also into a supply agreement with CCT, pursuant to which CCT will supply Company with the entire requirement of Biovance for distribution and sale in the United States. The Company's medical devices are subject to the U.S. Food and Drug Administration's general controls, which include compliance with the applicable portions of the U.S. Food and Drug Administration's Quality System Regulation, facility registration and product listing, reporting of adverse medical events, and appropriate, truthful and non-misleading labeling, advertising, and promotional materials. It is subject to various laws and governmental regulations concerning environmental matters and employee safety and health in the U
» More Articles for ALQA

Headlines

Articles On GuruFocus.com
CFO of Alliqua BioMedical Inc Buys 2,500 Shares Aug 12 2015 
Market Overlooks Alliqua’s First MAC Coverage Apr 21 2015 
Celleration Acquisition Just the Start of Alliqua’s M&A Strategy Feb 04 2015 

More From Other Websites
Alliqua BioMedical to Present at Upcoming Investor Conferences Feb 10 2016
Alliqua BioMedical, Inc. to Announce Fourth Quarter and Fiscal Year 2015 Results on February 23rd Feb 09 2016
Alliqua’s UltraMIST® System Honored With GOOD DESIGN Award Feb 04 2016
Alliqua Biomedical Announces Partnership With Human Longevity Inc., Under Existing Licensing... Jan 28 2016
ALLIQUA BIOMEDICAL, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 28 2016
Alliqua Biomedical Announces Partnership With Human Longevity Inc., Under Existing Licensing... Jan 28 2016
Alliqua BioMedical Announces Agreement With HealthTrust Jan 27 2016
Alliqua BioMedical Announces Agreement With HealthTrust Jan 27 2016
Alliqua BioMedical, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 18 2015
ALLIQUA BIOMEDICAL, INC. Financials Dec 08 2015
Direction of Market Influences - Research on Zion Oil and Gas, Alliqua Biomedical, MSB Financial and... Dec 03 2015
Is Imation Corp. (IMN) Going to Burn These Hedge Funds? Dec 02 2015
Is Alliqua Biomedical Inc (ALQA) A Good Stock To Buy? Nov 23 2015
ALLIQUA BIOMEDICAL, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Nov 12 2015
Alliqua BioMedical, Inc. to Attend November Healthcare Conferences Nov 09 2015
Alliqua reports 3Q loss Nov 05 2015
Alliqua reports 3Q loss Nov 05 2015
Alliqua BioMedical, Inc. Reports Third Quarter Financial Results Nov 05 2015
ALLIQUA BIOMEDICAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 05 2015
Alliqua BioMedical, Inc. to Announce Third Quarter of Fiscal Year 2015 Results on November 5th Oct 12 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK